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Abstract 
Primary dysmenorrhea is a common gynecologic disorder and is one of the main causes for referral to the 
gynecology clinic. This study aimed to determine the effects of alpha-lipoic acid (ALA) and mefenamic acid and 
a combination compared with placebo on the girls with primary dysmenorrhea. This double-blind, placebo-
controlled clinical trial done on population consisted of female students living in dormitories of Qazvin University of 
Medical Sciences who had moderate to severe dysmenorrhea using the Visual Analog Scale (VAS) questionnaire. 
Participants were randomly divided into four groups (n = 100): ALA, mefenamic acid, ALA + mefenamic acid and 
placebo groups. ALA and mefenamic acid were administrated in 600 mg and 250 mg, respectively. The severity of 
the pain was measured in the beginning and the end of the study. Statistical analysis was performed using SPSS 
software (SPSS Inc., Chicago, IL). Our final results suggested that, although mefenamic acid significantly 
decreased the menstrual pain, ALA supplementation, 600 mg, would be more efficient than mefenamic acid in 
250 mg. Also, the combination of ALA and mefenamic acid significantly has been far. Considering the ALA 
supplementation effect on pain relief in patients with primary dysmenorrhea, this antioxidant can be recommended 
for the healing of symptoms of these patients. 
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